Dr Kate Taylor is the CEO of Oculo. She initially trained as an ophthalmologist and holds an MPH from Johns Hopkins University as a Fulbright Scholar. She has worked in strategy, policy and advocacy with McKinsey & Company, the World Economic Forum’s Global Health Initiative, International AIDS Vaccine Initiative, and GlaxoSmithKline Biologicals. Her experience includes cutting-edge partnerships spanning new vaccine development through to innovative health financing, including the multi-billion dollar Advanced Market Commitment for pneumococcal vaccines and the Global Fund to Fight AIDS, Tuberculosis and Malaria. Kate also sits on the Independent Hospital Pricing Authority, the federal statutory body determining Australian hospital funding, as well as the Australian Digital Health Agency’s Clinical and Technical Advisory Committee.